32 research outputs found
Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms.
OBJECTIVE: To identify factors that determine disease severity and clinical
phenotype of the most common spinocerebellar ataxias (SCAs), we studied 526
patients with SCA1, SCA2, SCA3. or SCA6.
METHODS: To measure the severity of ataxia we used the Scale for the Assessment
and Rating of Ataxia (SARA). In addition, nonataxia symptoms were assessed with
the Inventory of Non-Ataxia Symptoms (INAS). The INAS count denotes the number of
nonataxia symptoms in each patient.
RESULTS: An analysis of covariance with SARA score as dependent variable and
repeat lengths of the expanded and normal allele, age at onset, and disease
duration as independent variables led to multivariate models that explained 60.4%
of the SARA score variance in SCA1, 45.4% in SCA2, 46.8% in SCA3, and 33.7% in
SCA6. In SCA1, SCA2, and SCA3, SARA was mainly determined by repeat length of the
expanded allele, age at onset, and disease duration. The only factors determining
the SARA score in SCA6 were age at onset and disease duration. The INAS count was
5.0 +/- 2.3 in SCA1, 4.6 +/- 2.2 in SCA2, 5.2 +/- 2.5 in SCA3, and 2.0 +/- 1.7 in
SCA6. In SCA1, SCA2, and SCA3, SARA score and disease duration were the strongest
predictors of the INAS count. In SCA6, only age at onset and disease duration had
an effect on the INAS count.
CONCLUSIONS: Our study suggests that spinocerebellar ataxia (SCA) 1, SCA2, and
SCA3 share a number of common biologic properties, whereas SCA6 is distinct in
that its phenotype is more determined by age than by disease-related factors
Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6.
Abstract: Onset of genetically determined neurodegenerative
diseases is difficult to specify because of their insidious and
slowly progressive nature. This is especially true for spinocerebellar
ataxia (SCA) because of varying affection of many
parts of the nervous system and huge variability of symptoms.
We investigated early symptoms in 287 patients with
SCA1, SCA2, SCA3, or SCA6 and calculated the influence
of CAG repeat length on age of onset depending on (1) the
definition of disease onset, (2) people defining onset, and (3)
duration of symptoms. Gait difficulty was the initial symptom
in two-thirds of patients. Double vision, dysarthria, impaired
hand writing, and episodic vertigo preceded ataxia in 4% of
patients, respectively. Frequency of other early symptoms did
not differ from controls and was regarded unspecific. Data
about disease onset varied between patients and relatives for
1 year or more in 44% of cases. Influence of repeat length
on age of onset was maximum when onset was defined as
beginning of permanent gait disturbance and cases with
symptoms for more than 10 years were excluded. Under
these conditions, CAG repeat length determined 64% of
onset variability in SCA1, 67% in SCA2, 46% in SCA3, and
41% in SCA6 demonstrating substantial influence of nonrepeat
factors on disease onset in all SCA subtypes. Identification
of these factors is of interest as potential targets for
disease modifying compounds. In this respect, recognition of
early symptoms that develop before onset of ataxia is mandatory
to determine the shift from presymptomatic to affected
status in SCA
SCAview: an Intuitive Visual Approach to the Integrative Analysis of Clinical Data in Spinocerebellar Ataxias
With SCAview, we present a prompt and comprehensive tool that enables scientists to browse large datasets of the most common spinocerebellar ataxias intuitively and without technical effort. Basic concept is a visualization of data, with a graphical handling and filtering to select and define subgroups and their comparison. Several plot types to visualize all data points resulting from the selected attributes are provided. The underlying synthetic cohort is based on clinical data from five different European and US longitudinal multicenter cohorts in spinocerebellar ataxia type 1, 2, 3, and 6 (SCA1, 2, 3, and 6) comprising > 1400 patients with overall > 5500 visits. First, we developed a common data model to integrate the clinical, demographic, and characterizing data of each source cohort. Second, the available datasets from each cohort were mapped onto the data model. Third, we created a synthetic cohort based on the cleaned dataset. With SCAview, we demonstrate the feasibility of mapping cohort data from different sources onto a common data model. The resulting browser-based visualization tool with a thoroughly graphical handling of the data offers researchers the unique possibility to visualize relationships and distributions of clinical data, to define subgroups and to further investigate them without any technical effort. Access to SCAview can be requested via the Ataxia Global Initiative and is free of charge
γ/δ T cell subsets in patients with active Mycobacterium tuberculosis infection and tuberculin anergy
Earlier data suggest that γ/δ T cells may play an important role in the immune response to Mycobacterium tuberculosis. The aim of this study was to determine the percentage of different γ/δ subsets in peripheral blood of active tuberculosis patients with a positive or negative tuberculin reaction. Thirty-eight patients infected with M. tuberculosis and 22 healthy controls were included in the study. Venous blood was taken before starting antimycobacterial treatment. Lymphocytes were reacted with monoclonal antibodies specific for different γ/δ V chains (Vδ1, Vδ2, Vγ9 and Vγ4). The results were analysed in the context of tuberculin reactivity and X-ray findings. Our results revealed a selective loss of Vγ9/Vδ2 T cells in the peripheral blood of tuberculin-negative patients with active tuberculosis compared to healthy controls, while the ratio of Vγ9/Vδ2 T cells in the peripheral blood of patients with a positive skin test did not differ from that of healthy controls. These findings demonstrate a relationship between the loss of the major M. tuberculosis-reactive subset of γδ T cells and the absence of tuberculin reactivity. The data are consistent with the hypothesis that γδ T cells play a role in the protective immune response to M. tuberculosis infection
Prospective analysis of falls in dominant ataxias
Item does not contain fulltextIn a previous retrospective study, we demonstrated that falls are common and often injurious in dominant spinocerebellar ataxias (SCAs) and that nonataxia features play an important role in these falls. Retrospective surveys are plagued by recall bias for the presence and details of prior falls. We therefore sought to corroborate and extend these retrospective findings by means of a prospective extension of this fall study. 113 patients with SCA1, SCA2, SCA3 or SCA6, recruited from the EuroSCA natural history study, were asked to keep a fall diary in between their annual visits to the participating centres. Additionally, patients completed a detailed questionnaire about the first three falls, to identify specific fall circumstances. Relevant disease characteristics were retrieved from the EuroSCA registry. 84.1% of patients reported at least one fall during a time period of 12 months. Fall-related injuries were common and their frequency increased with that of falls. The presence of nonataxia symptoms was associated with a higher fall frequency. This study confirms that falls are a frequent and serious complication of SCA, and that the presence of nonataxia symptoms is an important etiological factor in its occurrence
Use of a Paper Checklist to Increase Clinician Adherence to Mammography Screening Guidelines
Reliability and validity of the International Cooperative Ataxia Rating Scale: a study in 156 spinocerebellar ataxia patients.
Contains fulltext :
50512.pdf (publisher's version ) (Closed access)To evaluate the efficacy of treatments in spinocerebellar ataxias (SCAs), appropriate clinical scales are required. This study evaluated metric properties of the International Cooperative Ataxia Rating Scale (ICARS) in 156 SCA patients and 8 controls. ICARS was found to be a reliable scale satisfying accepted criteria for interrater reliability, test-retest reliability, and internal consistency. Although validity testing was limited, we found evidence of validity of ICARS when ataxia disease stages and Barthel index were used as external criteria. On the other hand, our study revealed two major problems associated with the use of ICARS. First, the redundant and overlapping nature of several items gave rise to a considerable number of contradictory ratings. Second, a factorial analysis showed that the rating results were determined by four different factors that did not coincide with the ICARS subscales, thus questioning the justification of ICARS subscore analysis in clinical trials